Business Wire

Goldman Sachs Invests in Aragen Life Sciences

Share

Aragen Life Sciences (“Aragen”), formerly known as GVK Biosciences and a leading contract research organization (CRO), announced today that Goldman Sachs, an active investor in India, has taken a significant minority stake in the company by acquiring shares previously held by ChrysCapital and other existing shareholders.

Aragen is a leading provider of outsourced discovery, development, and manufacturing services across both large and small molecule platforms. The company serves a worldwide customer base which spans to the United States, Europe, and Japan. Aragen has demonstrated strong organic growth on the back of deep domain expertise, strong global delivery capabilities, and partnerships with global biopharmaceutical and biotech clients.

“We believe this new investment at this important juncture in our company’s development underscores the tremendous opportunity ahead. Working with Goldman Sachs, we are well-positioned to address the opportunities in front of us to become a leading, global player with comprehensive end-to-end solutions for drug discovery and development,” said Manni Kantipudi, CEO of Aragen Life Sciences. “For more than five years, ChrysCapital has been a trusted investment partner. Following their successful exit, we are pleased to now enter a new phase in our continued evolution.”

“Aragen is well-positioned to benefit from the secular trend of increased outsourcing by the life sciences industry. With a clear value creation plan in place, we look forward to closely working with the management and shareholders of Aragen,” said Rajat Sood, a managing director at Goldman Sachs Asset Management. “Goldman Sachs is actively seeking to invest and foster leading, national champions of India who are building companies of a global scale.”

“As an experienced global investor in the healthcare sector and India, we look forward to leveraging our worldwide network and experience to help expand Aragen’s portfolio of differentiated offerings and client base to accelerate the company’s growth,” said Michael Bruun, a managing director at Goldman Sachs Asset Management.

Raghav Ramdev, Managing Director at ChrysCapital said, “We are proud to have seen Aragen grow and scale from providing discovery services to successfully expand into development and manufacturing, as well as biologics. It has evolved into an industry leader with a strong base of innovator clients.”

Goldman Sachs is an active investor in India, deploying more than $3.6 billion in capital since 2006. Previous investments in Indian healthcare include Biocon Biologics, BPL Medical Technologies, CyteCare Hospitals, Max India and Nova Medical Centers.

Jefferies, Dimensions, and Shardul Amarchand Mangaldas & Co advised company, existing shareholders and ChrysCapital. Trilegal, Herbert Smith Freehills, and Deloitte advised Goldman Sachs.

About Aragen Life Sciences

Aragen Life Sciences Pvt Ltd (“Aragen”) is a leader in discovery, development and manufacturing solutions. We offer differentiated contract research organization (CRO) and contract development and manufacturing organization (CDMO) solutions for small and large molecules. Through a presence across seven sites in India and overseas. Aragen employees over 3,000 professionals globally and serves more than 450 life sciences customers across biotech and large cap companies.

About Goldman Sachs Asset Management

Goldman Sachs is one of the world’s leading investors in alternative investments. With over 30 years of experience, we invest in the full spectrum of alternatives, including private equity, growth equity, credit, real estate, infrastructure, ESG, and absolute-return strategies. Our clients access these solutions through our direct proprietary strategies, customized strategic partnerships, and open-architecture programs. Our alternative investment teams represent over 1,000 professionals, across 50 offices around the world. We leverage the depth and breadth of global relationships across Goldman Sachs to identify investment opportunities, drawing on our firm-wide capital market insights, industry research, and risk management platforms. We extend these capabilities to the world’s leading pension plans, sovereign wealth funds, governments, financial institutions, endowments, foundations, family offices and individuals, for which we invest or advise on over $350 billion of alternative investments.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Aragen Life Sciences (Formerly known as GVK Biosciences): Sarat Patanaik, +91 95732 80064, sarat.patanaik@gvkbio.com
Goldman Sachs: Danika D’Souza, +91 98335 83779, DDSouza@webershandwick.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Quest Appoints Brian Brugman as Director of Research14.6.2021 14:00:00 CEST | Press release

Quest Partners LLC (“Quest”), a quantitative investment firm managing nearly $1.8 billion of assets on behalf of some of the world’s largest institutions, today announced that Brian Brugman joined the firm as Director of Research. In the role, Mr. Brugman will spearhead Quest’s research and investment strategy development alongside Quest’s Founder and Chief Investment Officer, Nigol Koulajian. He will also join Quest’s management committee. “Brian’s breadth of experience in designing quantitative strategies with considerations around convexity risk bodes well with Quest’s differentiated approach to systematic macro trading,” said Mr. Koulajian. “He is joining as we are nearing the completion of a multi-year process to build out a state-of-the-art investment infrastructure to dramatically increase the efficiency and scalability of our research process. Brian will play a critical role in leveraging that technology and our research team to pursue highly valuable, negatively correlated ret

Hisense's European Sales Revenue Surges to 113%, Successfully Strengthen European Competitive Position and Profitability14.6.2021 13:00:00 CEST | Press release

Hisense, the official sponsor of UEFA EURO 2020, celebrates the official kick-off of EURO 2020 in Italy. Football, as one of the top events in Europe, creates a chance for Hisense to build emotional connections with European consumers. Ever since the sponsorship of UEFA EURO 2016, through supporting sport event and technology innovation, Hisense gains many recognitions and praises from European consumers; its brand awareness increased by 6%. In 2021, Hisense’s sales revenue in the European market grew by 113% year-on-year, with more than 355% and 185% growth in key markets such as Poland and France. Hisense is dedicated to developing and producing cutting-edge technology, adopting localization strategy to ensure different markets' consumer needs and product experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210614005257/en/ Fans can find Hisense Logo on EURO 2020 Festival Tower (Photo: Business Wire) Localization man

Moody’s Highlights Its Commitment to Sustainability Leadership14.6.2021 13:00:00 CEST | Press release

Today Moody’s Corporation (NYSE:MCO) released its inaugural Stakeholder Sustainability and Diversity, Equity and Inclusion (DE&I) reports, which highlight its ongoing commitment to sustainability leadership by placing sustainability considerations at the core of its global business and operations. The 2020 Stakeholder Sustainability Report details Moody’s focus on sustainability and its progress toward incorporating environmental, social and governance (ESG) considerations across its products and corporate operations. Moody’s DE&I Report details new goals established to enhance diverse representation across its global workforce and highlights programs and partnerships created to advance DE&I in its workplace, communities and the wider business community. “Sustainability is an integral part of who we are and how we operate at Moody’s,” said Robert Fauber, President and Chief Executive Officer. “Our Stakeholder Sustainability and DE&I reports detail the many ways in which we are committe

Velodyne Lidar Introduces Next-Generation Velabit™ Sensor14.6.2021 12:48:00 CEST | Press release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today introduced the next generation of its Velabit™ sensor, which addresses the cost, safety, and design challenges of autonomous solutions while delivering state-of-the-art performance. Equipped with Velodyne's breakthrough proprietary micro-lidar array architecture (MLA), the Velabit delivers on what Velodyne customers asked for - an ultra-wide field of view (FoV) and higher resolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210614005080/en/ Velodyne Lidar introduced the next generation of its Velabit™ sensor, which addresses the cost, safety, and design challenges of autonomous solutions while delivering state-of-the-art performance. (Photo: Velodyne Lidar) The solid-state Velabit sensor now has a simultaneously achievable maximum horizontal FoV of 90° and maximum vertical FOV of 70°, approximately three times more points per second than the previous model. The next gene

Thales and Google Expand Partnership to Support Enhanced Privacy and Confidentiality Capabilities for Google Workspace14.6.2021 12:00:00 CEST | Press release

Thales today announced that its CipherTrust Manager and SafeNet Trusted Access have been integrated with Google Workspace Client-side encryption (beta coming soon), a new privacy and confidentiality offering for Google Workspace users. Providing enhanced key management capabilities and identity protection, customers can benefit from improved regulatory compliance and data ownership by allowing them to maintain ownership of keys used to encrypt Google Workspace documents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210614005060/en/ © Thales With many countries developing strict data security regulations, such as GDPR and Schrems II in Europe, CCPA in NORAM and NDB in APAC, the regulatory landscape is becoming increasingly complex for organisations to navigate. What’s more, with three-quarters (74%) of global organisations planning to keep part of their workforce remote after the pandemic, there is an increasing need for a

Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment14.6.2021 10:15:00 CEST | Press release

Celltrion Group today announced top-line efficacy and safety data from the global Phase III clinical trial, demonstrating that anti-COVID-19 monoclonal antibody treatment candidate, regdanvimab (CT-P59), met all primary and key secondary endpoints in patients with mild- to- moderate symptoms of COVID-19 (n=1,315). Results showed that CT-P59 significantly reduced the risk of hospitalisation or death by 72% for patients at high- risk of progressing to severe COVID-19 up to Day 28, compared to placebo, meeting the primary efficacy endpoint [3.1 vs. 11.1 %, p-value< 0.0001]. CT-P59 also significantly reduced the risk of hospitalisation or death by 70% in all patients, meeting the first key secondary endpoint [2.4 vs. 8.0 %, p-value< 0.0001]. The trial also met the other key secondary endpoints, including faster and persistent reduction in symptom duration. Patients treated with CT-P59 (40mg/kg) recovered at least 4.7 days earlier than those in the placebo-treated patients [median 9.3 vs. m

Immersive Labs Raises $75m to Accelerate Data Platform for Analyzing and Unlocking Cyber Skills Across Large Organizations14.6.2021 10:00:00 CEST | Press release

Immersive Labs, the company empowering organizations to measure and improve cybersecurity skills across technical and non-technical teams, today announced it has closed $75m in Series C funding led by new investors Insight Partners alongside Menlo Ventures, Citi Ventures and existing investor Goldman Sachs Asset Management. The investment will accelerate delivery of a progressive new Cyber Workforce Optimization platform. With cyber risk no longer confined to technical specialists, expert skills are now required across the entire organization. From crisis management with executives to secure software development amongst engineers and ensuring compliance in legal teams, the platform will use data insights to understand where skills are required and inject role-specific training. It will also enable board-level metrics and benchmarking. Immersive Labs, which has now received $123m in venture funding, currently counts organizations such as HSBC, Vodafone and the NHS as customers. Growing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom